Taysha Gene Therapies Reports 2025 Financial Results, Advances Rett Syndrome Trials, and Receives FDA Clearance for ASPIRE Trial.

Taysha Gene Therapies has reported its full-year 2025 financial results and provided a corporate update. The company has dosed multiple patients in the REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites. The FDA has cleared the initiation of the ASPIRE trial in three patients aged 2 to 4 years, with dosing expected to be completed in Q2 2026. The company maintains a favorable tolerability profile with no treatment-related SAEs or DLTs as of the March 2026 data cutoff. Longer-term safety and efficacy data from Part A of the REVEAL Phase 1/2 trials are expected in Q2 2026.